Ciphergen Announces Issuance of European Patent Covering a Method for Aiding Prostate Cancer Diagnosis
January 25 2007 - 8:00AM
PR Newswire (US)
FREMONT, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced that the European
Patient Office (EPO) has issued EU Patent No. 1 224 466, entitled
"Prostate Cancer Marker Proteins," for aiding in prostate cancer
diagnosis. The patent describes a method that measures certain
protein biomarkers that are present in the blood of patients with
prostate cancer versus patients who do not have prostate cancer.
"This patent is another example of Ciphergen's position as a
leading developer of novel high-value diagnostic tests, and our
intellectual property portfolio is growing in size and strength,"
said Gail S. Page, Chief Executive Officer of Ciphergen Biosystems.
"We continue to generate promising data for biomarkers that may be
useful for prostate cancer diagnosis, disease monitoring, or
prediction of recurrence." About Ciphergen's Prostate Cancer
Development Program Ciphergen has a diagnostic program in prostate
cancer and is evaluating a panel of biomarkers as potential tests
for prostate cancer diagnosis, progression and recurrence. In May
2006, Ciphergen and Johns Hopkins reported the discovery of two
biomarkers that, when combined with prostate-specific antigen
(PSA), were highly predictive of likelihood of recurrence of
prostate cancer. The data resulted from two studies -- one
examining over 400 men with prostate cancer, and the other
examining 50 pairs of men followed for five years with prostate
cancer matched for age, cancer stage and other clinical parameters.
These results suggest the potential for a test to 1) aid in the
diagnosis of prostate cancer; 2) aid in the stratification of risk
of highly aggressive prostate cancer, independent of other clinical
variables; 3) reduce over-treatment of prostate cancer in cases not
likely to be lethal and; 4) shift treatment to those cases that are
particularly likely to be lethal. Patent applications in the U.S.
and Japan are pending. Inventors on this patent include Dr.
Tai-Tung Yip, Senior Research Fellow at Ciphergen and inventor of
the SELDI technology, and Christine Yip, Senior Scientist at
Ciphergen. About Ciphergen Ciphergen Biosystems, Inc. is dedicated
to the discovery, development and commercialization of novel
high-value diagnostic tests that help physicians diagnose, treat
and improve outcomes for patients. Ciphergen, along with its
prestigious scientific collaborators, has ongoing diagnostic
programs in oncology/hematology, cardiology and women's health with
an initial focus in ovarian cancer. Based in Fremont, California,
more information about Ciphergen can be found on the web at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the continued growth of our
intellectual property portfolio and the efficacy and utility of our
diagnostic tests for prostate cancer diagnosis, progression and
recurrence. Actual results may differ materially from those
projected in such forward-looking statements due to various
factors, including the possibility that future development efforts
may not proceed as anticipated. Investors should consult
Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-Q filed November 20, 2006, for further
information regarding these and other risks related to the
Company's business. NOTE: Ciphergen is a registered trademark of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers, Investor Relations of Ciphergen
Biosystems, Inc., +1-510-505-2233; or media, Lori Murray of
WeissComm Partners, +1-415-946-1070, for Ciphergen Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Ciphergen Biosystems (MM) (NASDAQ): 0 recent articles
More Ciphergen Biosystems (MM) News Articles